CMC Strategy & Module 3 Authoring

What’s Included

• Module 3 gap assessment and section ownership. Mapping existing drug substance and drug product content against what a complete package requires, with named section ownership and a cross-reference checkpoint built into the authoring process — not a single pass at 100% draft.
• Specification justification packages. Building 3.2.S.4/3.2.P.5 specification tables on a documented three-tier chain — safety/toxicological basis, validated analytical capability (including LOQ discipline), and process history across representative batches — so every acceptance criterion has a traceable rationale, not just a number.
• Stability program design and retest-period defense. Designing ICH Q1A(R2)-compliant study matrices and the statistical analysis (ICH Q1E: pre-specified regression model, poolability testing, 95% lower confidence bound) that supports the proposed retest period or shelf life — the single most common source of stability-related information requests.
• QTPP-to-control-strategy traceability. Mapping each Quality Target Product Profile attribute through its linked Critical Quality Attribute, formulation/process design decision, and control strategy element, for programs building or defending a QbD-based development story.
• Drug product reference standard programs (3.2.P.6). Closing the gap between the drug substance reference standard cross-reference and the product-specific degradant, dissolution calibrator, and container-extractable standards a complete drug product analytical package actually requires.
• Quality Overall Summary authorship (Module 2.3). Writing QOS narratives that state the decision, cite the specific supporting data, and explain the significance for product quality — rather than restating section headings and forwarding the reviewer to Module 3.

When You Need This

• Your Module 3 specification table has limits that were set by convention or by the tightest observed batch result, without a documented chain back to toxicological, analytical, or process-capability evidence.
• You’re proposing a retest period or shelf life that extends beyond your observed stability data, and you need the statistical basis — not just the guideline citation — to survive review.
• Your QOS reads as an index to Module 3 rather than an argument, and you want reviewers to understand your scientific logic before they open a single section.

A Module 3 package that reads as internally consistent — where every specification, every stability claim, and every QOS statement traces to real supporting data — is the single biggest lever against a multi-cycle review. Request an assessment of your current package and we’ll show you exactly where that chain holds and where it doesn’t.